$AFJK
Aimei Health Technology Co., Ltd.

2024 Q4 Form 10-Q Financial Statement

#000149315224045119 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $200.0K
YoY Change
Operating Profit
YoY Change
Interest Expense $943.5K
YoY Change
% of Operating Profit
Other Income/Expense, Net $943.5K
YoY Change
Pretax Income $743.5K
YoY Change
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $743.5K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.08
COMMON SHARES
Basic Shares Outstanding 9.026M shares 9.026M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.6K
YoY Change
Cash & Equivalents $103.6K $10.00K
Short-Term Investments
Other Short-Term Assets $20.34K
YoY Change
Inventory
Prepaid Expenses $20.34K
Receivables
Other Receivables
Total Short-Term Assets $123.9K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $72.66M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $72.66M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $123.9K
Total Long-Term Assets $72.66M
Total Assets $72.78M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $142.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $230.8K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $690.0K
YoY Change
Total Long-Term Liabilities $690.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $230.8K
Total Long-Term Liabilities $690.0K
Total Liabilities $920.8K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$797.1K
YoY Change
Common Stock $213.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$796.9K $21.38K
YoY Change
Total Liabilities & Shareholders Equity $72.78M
YoY Change

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income $743.5K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$53.95K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -53.95K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -53.95K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$53.95K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Address Address Line1
EntityAddressAddressLine1
10 East 53rd Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3001
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001979005
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
+34
dei Local Phone Number
LocalPhoneNumber
678 035200
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9026000 shares
CY2024Q3 us-gaap Assets Current
AssetsCurrent
123900 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
580717 usd
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
72660715 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
69889848 usd
CY2024Q3 us-gaap Assets
Assets
72784615 usd
CY2023Q4 us-gaap Assets
Assets
70470565 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
142026 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24841 usd
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
AFJK Business Combination Description
BusinessCombinationDescription
If the Company is unable to complete a business combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding Public Shares which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining holders of ordinary shares and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2024Q3 us-gaap Share Price
SharePrice
10.10
CY2024Q3 us-gaap Cash
Cash
103559 usd
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
72660715 usd
CY2024Q3 AFJK Working Capital
WorkingCapital
106889 usd
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
usd
CY2023Q3 us-gaap Investment Income Dividend
InvestmentIncomeDividend
usd
us-gaap Investment Income Dividend
InvestmentIncomeDividend
usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2023Q2 AFJK Stock Issued During Period Value Issued For Subscription Receivable
StockIssuedDuringPeriodValueIssuedForSubscriptionReceivable
usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
usd
AFJK Interest Earned On Investments Held In Trust
InterestEarnedOnInvestmentsHeldInTrust
usd
us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
AFJK Remeasurement Of Carrying Value To Redemption Values
RemeasurementOfCarryingValueToRedemptionValues
usd
AFJK Deferred Offering Costs Included In Promissory Note
DeferredOfferingCostsIncludedInPromissoryNote
usd
AFJK Deferred Offering Costs Included In Accrued Offering Cost
DeferredOfferingCostsIncludedInAccruedOfferingCost
usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41880
dei Entity Registrant Name
EntityRegistrantName
AIMEI HEALTH TECHNOLOGY CO., LTD
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2024Q3 us-gaap Cash
Cash
103559 usd
CY2023Q4 us-gaap Cash
Cash
580717 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
20341 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
88763 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
230789 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24841 usd
CY2024Q3 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
690000 usd
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
690000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
920789 usd
CY2023Q4 us-gaap Liabilities
Liabilities
714841 usd
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6900000 shares
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6900000 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6900000 shares
CY2024Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.53
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.13
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
72660715 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
69889848 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
213 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
213 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-797102 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134337 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-796889 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-134124 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72784615 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70470565 usd
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
200019 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
662765 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3618 usd
CY2024Q3 us-gaap Investment Income Dividend
InvestmentIncomeDividend
943529 usd
us-gaap Investment Income Dividend
InvestmentIncomeDividend
2770867 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
943529 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2770867 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
743510 usd
us-gaap Net Income Loss
NetIncomeLoss
2108102 usd
us-gaap Net Income Loss
NetIncomeLoss
-3618 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
187500 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-134124 usd
CY2024Q1 AFJK Remeasurement Of Carrying Value To Redemption Value
RemeasurementOfCarryingValueToRedemptionValue
-909132 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
755500 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-287756 usd
CY2024Q2 AFJK Remeasurement Of Carrying Value To Redemption Value
RemeasurementOfCarryingValueToRedemptionValue
-918206 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
609092 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-596870 usd
CY2024Q3 AFJK Remeasurement Of Carrying Value To Redemption Value
RemeasurementOfCarryingValueToRedemptionValue
-943529 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
743510 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-796889 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3618 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3618 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3618 usd
CY2023Q3 AFJK Subscription Fee Received
SubscriptionFeeReceived
25000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
21382 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
21382 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
187500 shares
us-gaap Net Income Loss
NetIncomeLoss
2108102 usd
us-gaap Net Income Loss
NetIncomeLoss
-3618 usd
AFJK Interest Earned On Investments Held In Trust
InterestEarnedOnInvestmentsHeldInTrust
2770867 usd
us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
3618 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20341 usd
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-88763 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
117185 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-477158 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
15000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-477158 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
580717 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103559 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10000 usd
AFJK Remeasurement Of Carrying Value To Redemption Values
RemeasurementOfCarryingValueToRedemptionValues
2770867 usd
AFJK Deferred Offering Costs Included In Promissory Note
DeferredOfferingCostsIncludedInPromissoryNote
206533 usd
AFJK Deferred Offering Costs Included In Accrued Offering Cost
DeferredOfferingCostsIncludedInAccruedOfferingCost
3416 usd
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2023-04-27
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zEOpP3aa64c1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zWb9Pl4XgrO3">Use of estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed as of the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AIMEI HEALTH TECHNOLOGY CO., LTD</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO UNAUDITED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Cash
Cash
103559 usd
CY2023Q4 us-gaap Cash
Cash
580717 usd
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
72660715 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
69889848 usd
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2024Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
5000001 usd
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Net Income Loss
NetIncomeLoss
2108102 usd
us-gaap Net Income Loss
NetIncomeLoss
-3618 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
743510 usd
us-gaap Net Income Loss
NetIncomeLoss
-3618 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zHFeVYhY7Vyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zOGwN77BPjc9">Concentration of credit risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240930_zGd8O17FD5U7" title="FDIC insured amount">250,000</span>. As of September 30, 2024 and December 31, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. As of September 30, 2024 and December 31, 2023, $<span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_c20240930_zIdS1MEyUuJ4" title="FDIC uninsured amount">0</span> and $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zUcuC7TO5W6e" title="FDIC uninsured amount">330,717</span> was not insured, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
330717 usd
CY2024Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
72660715 usd
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
69889848 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
88763 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
90000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
25000 usd
CY2023Q3 us-gaap Cash
Cash
25000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2126000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2126000 shares
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares

Files In Submission

Name View Source Status
afjk-20240930_cal.xml Edgar Link unprocessable
0001493152-24-045119-index-headers.html Edgar Link pending
0001493152-24-045119-index.html Edgar Link pending
0001493152-24-045119.txt Edgar Link pending
0001493152-24-045119-xbrl.zip Edgar Link pending
afjk-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
afjk-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
afjk-20240930_def.xml Edgar Link unprocessable
afjk-20240930_lab.xml Edgar Link unprocessable